Protocol 10608, "A phase II trial of durvalumab with gemcitabine and cisplatin as neoadjuvant therapy for high-risk resectable intrahepatic cholangiocarcinoma" (NCT TBD)
Details
Age
Adult
Locations
University of Colorado Hospital
Principal Investigator
Sarah Davis
Study ID
Protocol Number: 24-0573
More information available at ClinicalTrials.gov: NCT06050252
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers